

Ref: FOI/GS/ID 7750

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

31 October 2022

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to the incidence and treatment of breast cancer.

You asked:

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

- a. Abemaciclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)*
- b. Abemaciclib + Fulvestrant*
- c. Alpelisib + Fulvestrant*
- d. Anthracycline (e.g. doxorubicin or epirubicin) as a single agent*
- e. Atezolizumab + Nab-paclitaxel/Paclitaxel*
- f. Capecitabine as a single agent*
- g. Eribulin as a single agent or in combination*
- h. Everolimus + Exemestane*
- i. Fulvestrant as a single agent*
- j. Lapatinib*
- k. Neratinib*
- l. Parp Inhibitors (Olaparib/Talazoparib)*
- m. Palbociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)*
- n. Palbociclib + Fulvestrant*
- o. Pembrolizumab*
- p. Platinum (e.g. carboplatin or cisplatin) as a single agent*
- q. Ribociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)*
- r. Ribociclib + Fulvestrant*
- s. Sacituzumab Govitecan*
- t. Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent*
- u. Taxane and/or Anthracycline in combination*

- v. *Trastuzumab as a single agent or in combination*
- w. *Trastuzumab emtansine*
- x. *Transtuzumab deruxtecan*
- y. *Any other active systemic anti-cancer therapy*

Q2. *Does your trust participate in any clinical trials for breast cancer? If so, can you please provide the name of each trial and the number of patients taking part.*

Trust response:

Q1.

- a. 5
- b. 3
- c. 0
- d. 0
- e. 3
- f. 30
- g. 2
- h. 5
- i. 0
- j. 0
- k. 0
- l. 0
- m. 72
- n. 26
- o. 0
- p. 3
- q. 8
- r. 0
- s. 4
- t. 21
- u. 50
- v. 86
- w. 17
- x. 1
- y. 1

2. The breast cancer trials currently have open are:

IRAS Number	Project Short title	Recruited (org)
1003435	persevERA Breast Cancer	2
259240	PALMIRA	15
273402	WO41554 A Study of GDC 0077 in patients with HR-Positive Breast Cancer	0
274252	SENTINUS	12
290151	Phase III study of Niraparib vs placebo in patients with Breast Cancer	1
293812	LiSENUM -Lymphatic imaging Sentinel Node Super-Res CEUS	8
95626	OPTIMA	43